The Technology Development Board under the Department of Science & Technology, Ministry of Science & Technology, has provided financial backing to Ceramat Private Limited for manufacturing custom bone grafts using 3D printing technology. The company, based in Palghar, Maharashtra, will develop patient-specific bone grafts made from indigenously produced calcium phosphate materials. This support aims to reduce India’s dependence on imported bone graft products in the orthopaedic and dental sectors.
What the project involves
Ceramat Private Limited already manufactures standard bone grafts and granules using conventional methods. The new initiative will extend this capability to create customised grafts tailored to individual patient anatomy. The company will employ two complementary 3D printing approaches: Digital Light Processing (DLP)-based printing and extrusion-based printing. Both techniques will work with bioceramic raw materials including hydroxyapatite, beta-tricalcium phosphate, biphasic calcium phosphate and bioactive glass.
These calcium phosphate materials chemically resemble natural bone composition and are widely used in implants and bone repair. The integration of 3D printing with indigenously manufactured materials is expected to enable production of complex geometries that match specific clinical needs. The project aligns with the Government of India’s Aatmanirbhar Bharat initiative and focus on domestic medical technology development.
Currently, a significant portion of advanced bone graft products used in India are imported. By developing domestic manufacturing capacity for patient-specific solutions, the initiative seeks to build a self-reliant supply chain while creating potential for export markets.
What this means for you
If you require bone graft surgery in future, there may be options for customised implants designed specifically for your anatomy rather than standard off-the-shelf products. Over time, such personalised solutions could become more affordable as domestic manufacturing expands and reduces import costs. For companies and researchers in the biomaterials sector, this project demonstrates the government’s willingness to fund advanced manufacturing capabilities that can compete globally.